Mark Ratain

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Maitland Michael L; Kasza Kristen E; Karrison Theodore; Moshier Kristin; Sit Laura; Black Henry R; Undevia Samir D; Stadler Walter M; Elliott William J; Ratain Mark J
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Sharma Manish R; Maitland Michael L; Ratain Mark J
Other Paradigms: Better Treatments Are Identified by Better Trials: The Value of Randomized Phase II Studies.
Zhang Wei; Catenacci Daniel V T; Duan Shiwei; Ratain Mark J
A survey of the population genetic variation in the human kinome.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Mark Ratain (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Maitland Michael L; Kasza Kristen E; Karrison Theodore; Moshier Kristin; Sit Laura; Black Henry R; Undevia Samir D; Stadler Walter M; Elliott William J; Ratain Mark J
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6250-7.
2009: Sharma Manish R; Maitland Michael L; Ratain Mark J
Other Paradigms: Better Treatments Are Identified by Better Trials: The Value of Randomized Phase II Studies.
Cancer journal (Sudbury, Mass.) 2009;15(5):426-30.
2009: Zhang Wei; Catenacci Daniel V T; Duan Shiwei; Ratain Mark J
A survey of the population genetic variation in the human kinome.
Journal of human genetics 2009;54(8):488-92.
2009: Hoskins Janelle M; Rosner Gary L; Ratain Mark J; McLeod Howard L; Innocenti Federico
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
Pharmacogenomics 2009;10(7):1139-46.
2009: Yong Wei Peng; Kim Tae Won; Undevia Samir D; Innocenti Federico; Ratain Mark J
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
European journal of cancer (Oxford, England : 1990) 2009;45(11):1904-8.
2009: Innocenti Federico; Kroetz Deanna L; Schuetz Erin; Dolan M Eileen; Ramírez Jacqueline; Relling Mary; Chen Peixian; Das Soma; Rosner Gary L; Ratain Mark J
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2604-14.
2009: Zhang Wei; He Lijun; Liu Wanqing; Sun Chang; Ratain Mark J
Exploring the relationship between polymorphic (TG/CA)n repeats in intron 1 regions and gene expression.
Human genomics 2009;3(3):236-45.
2009: Miller Antonius A; Murry Daryl J; Owzar Kouros; Hollis Donna R; Kennedy Erin B; Abou-Alfa Ghassan; Desai Apurva; Hwang Jimmy; Villalona-Calero Miguel A; Dees E Claire; Lewis Lionel D; Fakih Marwan G; Edelman Martin J; Millard Fred; Frank Richard C; Hohl Raymond J; Ratain Mark J
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1800-5.
2009: Innocenti Federico; Mirkov Snezana; Nagasubramanian Ramamoorthy; Ramírez Jacqueline; Liu Wanqing; Bleibel Wasim K; Shukla Sunita J; Hennessy Kathleen; Rosner Gary L; Cook Edwin; Eileen Dolan M; Ratain Mark J
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
Cancer chemotherapy and pharmacology 2009;63(5):881-7.
2009: Bartlett Nancy L; Johnson Jeffrey L; Wagner-Johnston Nina; Ratain Mark J; Peterson Bruce A;
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
Cancer chemotherapy and pharmacology 2009;63(5):793-8.
2009: Hartford Christine M; Desai Apurva A; Janisch Linda; Karrison Theodore; Rivera Victor M; Berk Lori; Loewy John W; Kindler Hedy; Stadler Walter M; Knowles Heather L; Bedrosian Camille; Ratain Mark J
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1428-34.
2009: Perera M A; Thirumaran R K; Cox N J; Hanauer S; Das S; Brimer-Cline C; Lamba V; Schuetz E G; Ratain M J; Di Rienzo A
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
The pharmacogenomics journal 2009;9(1):49-60.
2009: Huang R Stephanie; Ratain Mark J
Pharmacogenetics and pharmacogenomics of anticancer agents.
CA: a cancer journal for clinicians 2009;59(1):42-55.
2009: Ratain Mark J; Sargent Daniel J
Optimising the design of phase II oncology trials: the importance of randomisation.
European journal of cancer (Oxford, England : 1990) 2009;45(2):275-80.
2008: Hahn Olwen M; Yang Cheng; Medved Milica; Karczmar Gregory; Kistner Emily; Karrison Theodore; Manchen Elizabeth; Mitchell Myrosia; Ratain Mark J; Stadler Walter M
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(28):4572-8.
2008: Zhang Wei; Liu Wanqing; Poradosu Enrique; Ratain Mark J
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
Human genomics 2008;3(1):53-70.
2008: Rosner G L; Panetta J C; Innocenti F; Ratain M J
Pharmacogenetic pathway analysis of irinotecan.
Clinical pharmacology and therapeutics 2008;84(3):393-402.
2008: Conti R M; Meltzer D O; Ratain M J
Nonprofit biomedical companies.
Clinical pharmacology and therapeutics 2008;84(2):194-7.
2008: Undevia Samir D; Innocenti Federico; Ramirez Jacqueline; House Larry; Desai Apurva A; Skoog Linda A; Singh Deepti A; Karrison Theodore; Kindler Hedy L; Ratain Mark J
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2008;44(12):1684-92.
2008: Innocenti Federico; Liu Wanqing; Fackenthal Donna; Ramírez Jacqueline; Chen Peixian; Ye Xin; Wu Xiaolin; Zhang Wei; Mirkov Snezana; Das Soma; Cook Edwin; Ratain Mark J
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
Pharmacogenetics and genomics 2008;18(8):683-97.
2008: Stock Wendy; Undevia Samir D; Bivins Carol; Ravandi Farhad; Odenike Olatoyosi; Faderl Stefan; Rich Elizabeth; Borthakur Gautam; Godley Lucy; Verstovsek Srdan; Artz Andrew; Wierda William; Larson Richard A; Zhang Yanming; Cortes Jorge; Ratain Mark J; Giles Francis J
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Investigational new drugs 2008;26(4):331-8.
2008: Weiss Scott T; McLeod Howard L; Flockhart David A; Dolan M Eileen; Benowitz Neal L; Johnson Julie A; Ratain Mark J; Giacomini Kathleen M
Creating and evaluating genetic tests predictive of drug response.
Nature reviews. Drug discovery 2008;7(7):568-74.
2008: Perera Minoli A; Innocenti Federico; Ratain Mark J
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
Pharmacotherapy 2008;28(6):755-68.
2008: Odenike Olatoyosi M; Larson Richard A; Gajria Devika; Dolan M Eileen; Delaney Shannon M; Karrison Theodore G; Ratain Mark J; Stock Wendy
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Investigational new drugs 2008;26(3):233-9.
2008: Moreno-Vinasco Liliana; Gomberg-Maitland Mardi; Maitland Michael L; Desai Ankit A; Singleton Patrick A; Sammani Saad; Sam Lee; Liu Yang; Husain Aliya N; Lang Roberto M; Ratain Mark J; Lussier Yves A; Garcia Joe G N
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Physiological genomics 2008;33(2):278-91.
2008: Ramírez J; Mirkov S; Zhang W; Chen P; Das S; Liu W; Ratain M J; Innocenti F
Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.
The pharmacogenomics journal 2008;8(2):152-61.
2008: Rudin Charles M; Liu Wanqing; Desai Apurva; Karrison Theodore; Jiang Xuemin; Janisch Linda; Das Soma; Ramirez Jacqueline; Poonkuzhali Balasubramanian; Schuetz Erin; Fackenthal Donna Lee; Chen Peixian; Armstrong Deborah K; Brahmer Julie R; Fleming Gini F; Vokes Everett E; Carducci Michael A; Ratain Mark J
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1119-27.
2008: Daugherty Christopher K; Ratain Mark J; Emanuel Ezekiel J; Farrell Ann T; Schilsky Richard L
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1371-8.
2008: Ratain Mark J; Humphrey Rachel W; Gordon Gary B; Fyfe Gwen; Adamson Peter C; Fleming Thomas R; Stadler Walter M; Berry Donald A; Peck Carl C
Recommended changes to oncology clinical trial design: revolution or evolution?
European journal of cancer (Oxford, England : 1990) 2008;44(1):8-11.
2007: Ramírez Jacqueline; Liu Wanqing; Mirkov Snezana; Desai Apurva A; Chen Peixian; Das Soma; Innocenti Federico; Ratain Mark J
Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(12):2149-53.
2007: Liu Wanqing; Wu Xiaolin; Zhang Wei; Montenegro Raquel C; Fackenthal Donna Lee; Spitz Jared A; Huff Lyn Mickley; Innocenti Federico; Das Soma; Cook Edwin H; Cox Nancy J; Bates Susan E; Ratain Mark J
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(22 Pt 1):6788-95.
2007: Ratain Mark J; Glassman Robert H
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(22 Pt 1):6545-8.
2007: Chabner Bruce A; Ratain Mark J
Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6540.
2007: Yong Wei Peng; Desai Apurva A; Innocenti Federico; Ramirez Jacqueline; Shepard Dale; Kobayashi Ken; House Larry; Fleming Gini F; Vogelzang Nicholas J; Schilsky Richard L; Ratain Mark J
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2007;60(6):811-9.
2007: Ratain Mark J
The investigational drug steering committee.
Clinical advances in hematology & oncology : H&O 2007;5(10):779-80.
2007: Maitland Michael L; Ratain Mark J; Cox Nancy J
Interpreting P values in pharmacogenetic studies: a call for process and perspective.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4513-5.
2007: Karrison Theodore G; Maitland Michael L; Stadler Walter M; Ratain Mark J
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Journal of the National Cancer Institute 2007;99(19):1455-61.
2007: Hartford C M; Ratain M J
Rapamycin: something old, something new, sometimes borrowed and now renewed.
Clinical pharmacology and therapeutics 2007;82(4):381-8.
2007: Gray Stacy W; Hlubocky Fay J; Ratain Mark J; Daugherty Christopher K
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3488-94.
2007: Ratain Mark J; Cohen Ezra E
The value meal: how to save $1,700 per month or more on lapatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3397-8.
2007: Yoder Graber Andrea L; Ramírez Jacqueline; Innocenti Federico; Ratain Mark J
UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.
Pharmacogenetics and genomics 2007;17(8):619-27.
2007: Miller Antonius A; Murry Daryl J; Owzar Kouros; Hollis Donna R; Lewis Lionel D; Kindler Hedy L; Marshall John L; Villalona-Calero Miguel A; Edelman Martin J; Hohl Raymond J; Lichtman Stuart M; Ratain Mark J
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3055-60.
2007: Lewis Lionel D; Miller Antonius A; Rosner Gary L; Dowell Jonathan E; Valdivieso Manuel; Relling Mary V; Egorin Merrill J; Bies Robert R; Hollis Donna R; Levine Ellis G; Otterson Gregory A; Millard Frederick; Ratain Mark J;
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3302-11.
2007: Michaelis Laura C; Ratain Mark J
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2400-5.
2007: Ratain M J
Personalized medicine: building the GPS to take us there.
Clinical pharmacology and therapeutics 2007;81(3):321-2.
2007: Parsad Sandeep D; Ratain Mark J
Prescribing oral chemotherapy.
BMJ (Clinical research ed.) 2007;334(7590):376.
2007: Otterson Gregory A; Villalona-Calero Miguel A; Sharma Sunil; Kris Mark G; Imondi Anthony; Gerber Mirjam; White Dorothy A; Ratain Mark J; Schiller Joan H; Sandler Alan; Kraut Michael; Mani Sridhar; Murren John R
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1246-52.
2007: Hlubocky Fay J; Ratain Mark J; Wen Ming; Daugherty Christopher K
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):548-54.
2007: Ratain Mark J; Karrison Theodore G
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(3):781-2.
2007: Mirkov Snezana; Komoroski Bernard J; Ramírez Jacqueline; Graber Andrea Yoder; Ratain Mark J; Strom Stephen C; Innocenti Federico
Effects of green tea compounds on irinotecan metabolism.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(2):228-33.
2007: Ramchandani Roshni P; Wang Yaning; Booth Brian P; Ibrahim Amna; Johnson John R; Rahman Atiqur; Mehta Mehul; Innocenti Federico; Ratain Mark J; Gobburu Jogarao V S
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Journal of clinical pharmacology 2007;47(1):78-86.
2007: Zhang Wei; Liu Wanqing; Innocenti Federico; Ratain Mark J
Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms.
PloS one 2007;2(4):e396.
2006: Innocenti Federico; Ratain Mark J
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Pharmacogenomics 2006;7(8):1211-21.
2006: Roden Dan M; Altman Russ B; Benowitz Neal L; Flockhart David A; Giacomini Kathleen M; Johnson Julie A; Krauss Ronald M; McLeod Howard L; Ratain Mark J; Relling Mary V; Ring Huijun Z; Shuldiner Alan R; Weinshilboum Richard M; Weiss Scott T;
Pharmacogenomics: challenges and opportunities.
Annals of internal medicine 2006;145(10):749-57.
2006: Maitland Michael L; Ratain Mark J
Terminal ballistics of kinase inhibitors: there are no magic bullets.
Annals of internal medicine 2006;145(9):702-3.
2006: Lacouture M E; Desai A; Soltani K; Petronic-Rosic V; Laumann A E; Ratain M J; Stadler W M
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
Clinical and experimental dermatology 2006;31(6):783-5.
2006: Eisen T; Ahmad T; Flaherty K T; Gore M; Kaye S; Marais R; Gibbens I; Hackett S; James M; Schuchter L M; Nathanson K L; Xia C; Simantov R; Schwartz B; Poulin-Costello M; O'Dwyer P J; Ratain M J
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
British journal of cancer 2006;95(5):581-6.
2006: Maitland Michael L; Vasisht Kaveeta; Ratain Mark J
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Trends in pharmacological sciences 2006;27(8):432-7.
2006: Yong Wei Peng; Innocenti Federico; Ratain Mark J
The role of pharmacogenetics in cancer therapeutics.
British journal of clinical pharmacology 2006;62(1):35-46.
2006: Ratain Mark J; Miller Antonius A; McLeod Howard L; Venook Alan P; Egorin Merrill J; Schilsky Richard L
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3612s-6s.
2006: Ratain Mark J; Eisen Tim; Stadler Walter M; Flaherty Keith T; Kaye Stan B; Rosner Gary L; Gore Martin; Desai Apurva A; Patnaik Amita; Xiong Henry Q; Rowinsky Eric; Abbruzzese James L; Xia Chenghua; Simantov Ronit; Schwartz Brian; O'Dwyer Peter J
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2505-12.
2006: Maitland Michael L; DiRienzo Anna; Ratain Mark J
Interpreting disparate responses to cancer therapy: the role of human population genetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(14):2151-7.
2006: Innocenti Federico; Vokes Everett E; Ratain Mark J
Irinogenetics: what is the right star?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2221-4.
2006: Michaelis Laura C; Ratain Mark J
Measuring response in a post-RECIST world: from black and white to shades of grey.
Nature reviews. Cancer 2006;6(5):409-14.
2006: Lichtman Stuart M; Hollis Donna; Miller Antonius A; Rosner Gary L; Rhoades Chris A; Lester Eric P; Millard Frederick; Byrd John; Cullinan Stephen A; Rosen D Marc; Parise Robert A; Ratain Mark J; Egorin Merrill J;
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1846-51.
2006: Ratain Mark J
From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1658-60.
2006: Ramírez Jacqueline; Komoroski Bernard J; Mirkov Snezana; Graber Andrea Yoder; Fackenthal Donna Lee; Schuetz Erin G; Das Soma; Ratain Mark J; Innocenti Federico; Strom Stephen C
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes.
Pharmacogenetics and genomics 2006;16(2):79-86.
2006: Klein Cheri E; Kastrissios Helen; Miller Antonius A; Hollis Donna; Yu Daohai; Rosner Gary L; Grinblatt David L; Larson Richard A; Ratain Mark J
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
Cancer chemotherapy and pharmacology 2006;57(2):199-206.
2005: Andersson Tommy; Flockhart David A; Goldstein David B; Huang Shiew-Mei; Kroetz Deanna L; Milos Patrice M; Ratain Mark J; Thummel Kenneth
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
Clinical pharmacology and therapeutics 2005;78(6):559-81.
2005: Stadler Walter M; Michaelis Laura C; Ratain Mark J
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8124-5; author reply 8125-6.
2005: Desai Apurva A; Kindler Hedy L; Taber David; Agamah Edem; Mani Sridhar; Wade-Oliver Kurombi; Ratain Mark J; Vokes Everett E
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2005;56(4):421-6.
2005: Yong Wei Peng; Ramirez Jacqueline; Innocenti Federico; Ratain Mark J
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6699-704.
2005: Ratain Mark J
Phase II oncology trials: let's be positive.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5661-2.
2005: Undevia Samir D; Gomez-Abuin Gonzalo; Ratain Mark J
Pharmacokinetic variability of anticancer agents.
Nature reviews. Cancer 2005;5(6):447-58.
2005: Stadler Walter M; Rosner Gary; Small Eric; Hollis Donna; Rini Brian; Zaentz S Donald; Mahoney John; Ratain Mark J
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3726-32.
2005: French Deborah; Wilkinson Mark R; Yang Wenjian; de Chaisemartin Luc; Cook Edwin H; Das Soma; Ratain Mark J; Evans William E; Downing James R; Pui Ching-Hon; Relling Mary V
Global gene expression as a function of germline genetic variation.
Human molecular genetics 2005;14(12):1621-9.
2005: Desai A A; Schilsky R L; Young A; Janisch L; Stadler W M; Vogelzang N J; Cadden S; Wright J A; Ratain M J
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(6):958-65.
2005: Innocenti Federico; Liu Wanqing; Chen Peixian; Desai Apurva A; Das Soma; Ratain Mark J
Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.
Pharmacogenetics and genomics 2005;15(5):295-301.
2005: Liu Wanqing; Innocenti Federico; Ratain Mark J
Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):1348-9; author reply 1349.
2005: Liu Wanqing; Innocenti Federico; Wu Michael H; Desai Apurva A; Dolan M Eileen; Cook Edwin H; Ratain Mark J
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.
Cancer research 2005;65(1):46-53.
2005: Marshall John L; Kindler Hedy; Deeken John; Bhargava Pankaj; Vogelzang Nicholas J; Rizvi Naiyer; Luhtala Taina; Boylan Stacy; Dordal Margaret; Robertson Philmore; Hawkins Michael J; Ratain Mark J
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
Investigational new drugs 2005;23(1):31-7.
2005: Desai Apurva A; Ratain Mark J
EGFR pharmacogenomics: the story continues to mutate and evolve.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(2):137-9.
2004: Miller Antonius A; Rosner Gary L; Egorin Merrill J; Hollis Donna; Lichtman Stuart M; Ratain Mark J
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8325-31.
2004: Zimmerman Todd M; Harlin Helena; Odenike Olatoyosi M; Berk Seth; Sprague Evie; Karrison Theodore; Stock Wendy; Larson Richard A; Ratain Mark J; Gajewski Thomas F
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4816-22.
2004: Odenike Olatoyosi M; Sobecks Ronald M; Janisch Linda; Huo Dezheng; Zimmerman Todd M; Daugherty Christopher K; Ratain Mark J; Larson Richard A
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Cancer chemotherapy and pharmacology 2004;54(6):553-61.
2004: Innocenti Federico; Undevia Samir D; Ramírez Jacqueline; Mani Sridhar; Schilsky Richard L; Vogelzang Nicholas J; Prado Marisol; Ratain Mark J
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Clinical pharmacology and therapeutics 2004;76(5):490-502.
2004: Rudin Charles M; Marshall John L; Huang Chao Hui; Kindler Hedy L; Zhang Chuanbo; Kumar Deepak; Gokhale Prafulla C; Steinberg Joyce; Wanaski Steve; Kasid Usha N; Ratain Mark J
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7244-51.
2004: Undevia S D; Kindler H L; Janisch L; Olson S C; Schilsky R L; Vogelzang N J; Kimmel K A; Macek T A; Ratain M J
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(11):1705-11.
2004: Ahles Tim A; Herndon James E; Small Eric J; Vogelzang Nicholas J; Kornblith Alice B; Ratain Mark J; Stadler Walter; Palchak David; Marshall M Ernest; Wilding George; Petrylak Daniel; Holland Jimmie C;
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Cancer 2004;101(10):2202-8.
2004: Ratain Mark J; Eckhardt S Gail
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4442-5.
2004: Undevia Samir D; Vogelzang Nicholas J; Mauer Ann M; Janisch Linda; Mani Sridhar; Ratain Mark J
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
Investigational new drugs 2004;22(4):449-58.
2004: Desai Apurva A; Innocenti Federico; Janisch Linda; DeMario Mark; Shepard Dale; Ramirez Jacqueline; Fleming Gini F; Ratain Mark J
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2004;54(5):377-84.
2004: Ramírez Jacqueline; Innocenti Federico; Schuetz Erin G; Flockhart David A; Relling Mary V; Santucci Raymond; Ratain Mark J
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(9):930-6.
2004: Ryan Christopher W; Vogelzang Nicholas J; Vokes Everett E; Kindler Hedy L; Undevia Samir D; Humerickhouse Rod; André Amy K; Wang Qiang; Carr Robert A; Ratain Mark J
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4406-11.
2004: Helft Paul R; Schilsky Richard L; Hoke Frank J; Williams Daphne; Kindler Hedy L; Sprague Evie; DeWitte Mark; Martino Helen K; Erickson John; Pandite Lini; Russo Mark; Lambert John M; Howard Maria; Ratain Mark J
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4363-8.
2004: Dolan M Eileen; Newbold Karla G; Nagasubramanian Ramamoorthy; Wu Xiaolin; Ratain Mark J; Cook Edwin H; Badner Judith A
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
Cancer research 2004;64(12):4353-6.
2004: Innocenti Federico; Ratain Mark J
"Irinogenetics" and UGT1A: from genotypes to haplotypes.
Clinical pharmacology and therapeutics 2004;75(6):495-500.
2004: Helft Paul R; Ratain Mark J; Epstein Richard A; Siegler Mark
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
Journal of the National Cancer Institute 2004;96(9):656-61.
2004: Meyerhardt Jeffrey A; Kwok Ambrose; Ratain Mark J; McGovren J Patrick; Fuchs Charles S
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1439-46.
2004: Innocenti Federico; Undevia Samir D; Iyer Lalitha; Chen Pei Xian; Das Soma; Kocherginsky Masha; Karrison Theodore; Janisch Linda; Ramírez Jacqueline; Rudin Charles M; Vokes Everett E; Ratain Mark J
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1382-8.
2004: Kimmick Gretchen; Ratain Mark J; Berry Don; Woolf Susan; Norton Larry; Muss Hyman B;
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
Investigational new drugs 2004;22(1):83-9.
2004: Vogelzang Nicholas J; Karrison Theodore; Stadler Walter M; Garcia Juan; Cohn Helene; Kugler John; Troeger Thomas; Giannone Leonard; Arrieta Rose; Ratain Mark J; Vokes Everett E
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Cancer 2004;100(1):65-71.
2003: Venook A P; Enders Klein C; Fleming G; Hollis D; Leichman C G; Hohl R; Byrd J; Budman D; Villalona M; Marshall J; Rosner G L; Ramirez J; Kastrissios H; Ratain M J
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1783-90.
2003: Ratain Mark J
Finding the right dose.
Clinical advances in hematology & oncology : H&O 2003;1(9):517-8, 531.
2003: Desai Apurva A; Innocenti Federico; Ratain Mark J
Pharmacogenomics: road to anticancer therapeutics nirvana?
Oncogene 2003;22(42):6621-8.
2003: Desai Apurva A; Innocenti Federico; Ratain Mark J
UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.
Pharmacogenetics 2003;13(8):517-23.
2003: Murray Patrick T; Ratain Mark J
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2633-5.
2003: Fleming G F; Schilsky R L; Schumm L P; Meyerson A; Hong A M; Vogelzang N J; Ratain M J
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(7):1142-7.
2003: Sawyer Michael B; Innocenti Federico; Das Soma; Cheng Cheng; Ramírez Jacqueline; Pantle-Fisher Friedl H; Wright Constance; Badner Judith; Pei Deqing; Boyett James M; Cook Edwin; Ratain Mark J
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
Clinical pharmacology and therapeutics 2003;73(6):566-74.
2003: Innocenti Federico; Ratain Mark J
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Oncology (Williston Park, N.Y.) 2003;17(5 Suppl 5):52-5.
2003: Akerley Wallace; Herndon James E; Egorin Merrill J; Lyss Alan P; Kindler Hedy L; Savarese Dianne M; Sherman Carol A; Rosen D Marc; Hollis Donna; Ratain Mark J; Green Mark R
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Cancer 2003;97(10):2480-6.
2003: Sawyer Michael B; Ratain Mark J; Bertucci Donna; Smith Robert P; Schilsky Richard L; Vogelzang Nicholas J; Shulman Keith; Douglass Edwin C; Fleming Gini F
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1859-65.
2003: Liu Wanqing; Innocenti Federico; Chen Peixian; Das Soma; Cook Edwin H; Ratain Mark J
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):1009-12.
2003: Masters Gregory A; Brockstein Bruce E; Mani Sridhar; Ratain Mark J
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Medical oncology (Northwood, London, England) 2003;20(1):7-12.
2003: Nagasubramanian R; Innocenti F; Ratain M J
Pharmacogenetics in cancer treatment.
Annual review of medicine 2003;54():437-52.
2002: Klein Cheri Enders; Gupta Elora; Reid Joel M; Atherton Pamela J; Sloan Jeff A; Pitot Henry C; Ratain Mark J; Kastrissios Helen
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Clinical pharmacology and therapeutics 2002;72(6):638-47.
2002: Fleming Gini F; Meropol Neal J; Rosner Gary L; Hollis Donna R; Carson William E; Caligiuri Michael; Mortimer Joanne; Tkaczuk Katherine; Parihar Robin; Schilsky Richard L; Ratain Mark J
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3718-27.
2002: Innocenti Federico; Grimsley Carrie; Das Soma; Ramírez Jacqueline; Cheng Cheng; Kuttab-Boulos Hala; Ratain Mark J; Di Rienzo Anna
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
Pharmacogenetics 2002;12(9):725-33.
2002: Rosner Gary L; Stadler Walter; Ratain Mark J
Randomized discontinuation design: application to cytostatic antineoplastic agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(22):4478-84.
2002: Schellens Jan H M; Ratain Mark J
Endostatin: are the 2 years up yet?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3758-60.
2002: Small Eric J; Halabi Susan; Ratain Mark J; Rosner Gary; Stadler Walter; Palchak David; Marshall Ernest; Rago Randall; Hars Vera; Wilding George; Petrylak Daniel; Vogelzang Nicholas J
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3369-75.
2002: Lathia Chetan; Fleming Gini F; Meyer Mark; Ratain Mark J; Whitfield Lloyd
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Cancer chemotherapy and pharmacology 2002;50(2):121-6.
2002: Dolan M Eileen; Posner Mitchell; Karrison Theodore; Radosta Jonathan; Steinberg Gary; Bertucci Donna; Vujasin Lucky; Ratain Mark J
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2519-23.
2002: Ryan Christopher W; Vokes Everett E; Vogelzang Nicholas J; Janisch Linda; Kobayashi Ken; Ratain Mark J
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2002;50(1):1-5.
2002: Ramírez Jacqueline; Iyer Lalitha; Journault Kim; Bélanger Patrick; Innocenti Federico; Ratain Mark J; Guillemette Chantal
In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.
Pharmaceutical research 2002;19(5):588-94.
2002: Innocenti Federico; Ratain Mark J
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1314; author reply 1315-6.
2002: Shepard Dale R; Mani Sridhar; Kastrissios Helen; Learned-Coughlin Susan; Smith Deborah; Ertel Phillip; Magnum Steve; Janisch Linda; Fleming Gini F; Schilsky Richard L; Ratain Mark J
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
Cancer chemotherapy and pharmacology 2002;49(5):398-402.
2002: Mani Sridhar; Rudin Charles M; Kunkel Katie; Holmlund Jon T; Geary Richard S; Kindler Hedy L; Dorr F Andrew; Ratain Mark J
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1042-8.
2002: Iyer Lalitha; Ramírez Jacqueline; Shepard Dale R; Bingham Christopher M; Hossfeld Dieter-Kurt; Ratain Mark J; Mayer Ulrich
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
Cancer chemotherapy and pharmacology 2002;49(4):336-41.
2002: Innocenti F; Ratain M J
Update on pharmacogenetics in cancer chemotherapy.
European journal of cancer (Oxford, England : 1990) 2002;38(5):639-44.
2002: Ratain Mark J
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1434-5.
2002: Goh B C; Vokes E E; Joshi A; Ratain M J
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.
British journal of cancer 2002;86(4):534-9.
2002: Schilsky Richard L; Bertucci Donna; Vogelzang Nicholas J; Kindler Hedy L; Ratain Mark J
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):582-7.
2002: Ratain Mark J
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):7-8.
2002: Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming G F; Vokes E E; Schilsky R L; Ratain M J
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
The pharmacogenomics journal 2002;2(1):43-7.
2001: Eng C; Mauer A M; Fleming G F; Bertucci D; Rotmensch J; Jacobs R H; Ratain M J
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(12):1743-7.
2001: Mani S; Vogelzang N J; Bertucci D; Stadler W M; Schilsky R L; Ratain M J
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Cancer 2001;92(6):1567-76.
2001: Sawyer M; Ratain M J
Body surface area as a determinant of pharmacokinetics and drug dosing.
Investigational new drugs 2001;19(2):171-7.
2001: Rudin C M; Holmlund J; Fleming G F; Mani S; Stadler W M; Schumm P; Monia B P; Johnston J F; Geary R; Yu R Z; Kwoh T J; Dorr F A; Ratain M J
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1214-20.
2001: Innocenti F; Iyer L; Ramírez J; Green M D; Ratain M J
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(5):686-92.
2001: Ewesuedo R B; Iyer L; Das S; Koenig A; Mani S; Vogelzang N J; Schilsky R L; Brenckman W; Ratain M J
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2084-90.
2001: Innocenti F; Iyer L; Ratain M J
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 2):596-600.
2001: Goh B C; Ratain M J; Bertucci D; Smith R; Mani S; Vogelzang N J; Schilsky R L; Hutchison M; Smith M; Averbuch S; Douglass E
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1476-84.
2001: Kastrissios H; Ratain M J
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
Cancer investigation 2001;19(1):57-64.
2000: Innocenti F; Iyer L; Ratain M J
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Clinical pharmacokinetics 2000;39(5):315-25.
2000: Innocenti F; Stadler W M; Iyer L; Ramírez J; Vokes E E; Ratain M J
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3400-5.
2000: Schilsky R L; Dolan M E; Bertucci D; Ewesuedo R B; Vogelzang N J; Mani S; Wilson L R; Ratain M J
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3025-31.
2000: Venook A P; Egorin M J; Rosner G L; Hollis D; Mani S; Hawkins M; Byrd J; Hohl R; Budman D; Meropol N J; Ratain M J
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2780-7.
2000: Ryan C W; Fleming G F; Janisch L; Ratain M J
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
American journal of clinical oncology 2000;23(3):297-300.
2000: Daugherty C K; Banik D M; Janish L; Ratain M J
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.
IRB 2000;22(3):6-14.
2000: Stadler W M; Ratain M J
Development of target-based antineoplastic agents.
Investigational new drugs 2000;18(1):7-16.
2000: Goh B C; Fleming G F; Janisch L; Vogelzang N J; Stadler W M; Ratain M J
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
Cancer chemotherapy and pharmacology 2000;45(6):489-94.
1999: Vokes E E; Goh B C; Bertucci D; Vogelzang N J; Mani S; Ratain M J
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Cancer 1999;86(3):528-32.
1999: Minami H; Lad T E; Nicholas M K; Vokes E E; Ratain M J
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1325-30.
1999: Iyer L; Hall D; Das S; Mortell M A; Ramírez J; Kim S; Di Rienzo A; Ratain M J
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Clinical pharmacology and therapeutics 1999;65(5):576-82.
1999: Humerickhouse R A; Dolan M E; Haraf D J; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain M J; Vokes E E
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):291-8.
1999: Iyer L; Ratain M J
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
Cancer investigation 1999;17(7):494-506.
1999: DeMario M D; Ratain M J; Vogelzang N J; Mani S; Vokes E E; Fleming G F; Melton K; Johnson S; Benner S; Lebwohl D
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
Cancer chemotherapy and pharmacology 1999;43(5):385-8.
1998: House L K; Ramírez J; Ratain M J
Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns.
Journal of chromatography. B, Biomedical sciences and applications 1998;720(1-2):245-50.
1998: Vokes E E; Ansari R H; Masters G A; Hoffman P C; Klepsch A; Ratain M J; Sciortino D F; Lad T E; Krauss S; Fishkin P A; Golomb H M
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(10):1085-90.
1998: Iyer L; Ratain M J
Pharmacogenetics and cancer chemotherapy.
European journal of cancer (Oxford, England : 1990) 1998;34(10):1493-9.
1998: DeMario M D; Ratain M J
Oral chemotherapy: rationale and future directions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2557-67.
1998: Daugherty C K; Ratain M J; Minami H; Banik D M; Vogelzang N J; Stadler W M; Siegler M
Study of cohort-specific consent and patient control in phase I cancer trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2305-12.
1998: Fleming G F; Kugler J W; Hoffman P C; Ansari R; Bitran J D; Klepsch A; Malone D; Fasanmade A A; Ratain M J; Vokes E E
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2032-7.
1998: Dolan M E; Roy S K; Fasanmade A A; Paras P R; Schilsky R L; Ratain M J
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1803-10.
1998: Vogelzang N J; Mani S; Schilsky R L; Ansari R H; Taber D; Rhinehart S N; Garcia J C; Meyer S C; Mick R; Brockstein B E; Stadler W M; Ratain M J; Vokes E E
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):929-34.
1998: Schilsky R L; Hohneker J; Ratain M J; Janisch L; Smetzer L; Lucas V S; Khor S P; Diasio R; Von Hoff D D; Burris H A
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1450-7.
1998: Rini B I; Stadler W M; Spielberger R T; Ratain M J; Vogelzang N J
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.
Cancer 1998;82(7):1352-8.
1998: Brockstein B; Haraf D J; Stenson K; Fasanmade A; Stupp R; Glisson B; Lippman S M; Ratain M J; Sulzen L; Klepsch A; Weichselbaum R R; Vokes E E
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):735-44.
1998: Iyer L; King C D; Whitington P F; Green M D; Roy S K; Tephly T R; Coffman B L; Ratain M J
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
The Journal of clinical investigation 1998;101(4):847-54.
1998: Iyer L; Ratain M J
Clinical pharmacology of camptothecins.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S31-43.
1998: Mani S; Iyer L; Janisch L; Wang X; Fleming G F; Schilsky R L; Ratain M J
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
Cancer chemotherapy and pharmacology 1998;42(1):84-7.
1997: DeMario M D; Ratain M J
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):26-9.
1997: Ratain M J; Skoog L A; O'Brien S M; Cooper N; Schilsky R L; Vogelzang N J; Gerber M; Narang P K; Nicol S J
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(8):807-9.
1997: Daugherty C K; Siegler M; Ratain M J; Zimmer G
Learning from our patients: one participant's impact on clinical trial research and informed consent.
Annals of internal medicine 1997;126(11):892-7.
1997: Gupta E; Mick R; Ramirez J; Wang X; Lestingi T M; Vokes E E; Ratain M J
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1502-10.
1997: Mani S; Ratain M J
New phase I trial methodology.
Seminars in oncology 1997;24(2):253-61.
1997: Soliven B; Dhand U K; Kobayashi K; Arora R; Martin B; Petersen M V; Janisch L; Vogelzang N J; Vokes E E; Ratain M J
Evaluation of neuropathy in patients on suramin treatment.
Muscle & nerve 1997;20(1):83-91.
1997: Gupta E; Wang X; Ramirez J; Ratain M J
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
Cancer chemotherapy and pharmacology 1997;39(5):440-4.
1997: Ramírez J; Ogan K; Ratain M J
Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.
Cancer chemotherapy and pharmacology 1997;39(4):286-90.
1997: Fleming G F; O'Brien S M; Hoffman P C; Vokes E E; Vogelzang N J; Schilsky R L; Waggoner S E; Ratain M J
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Cancer chemotherapy and pharmacology 1997;39(3):227-32.
1996: Kobayashi K; Weiss R E; Vogelzang N J; Vokes E E; Janisch L; Ratain M J
Mineralocorticoid insufficiency due to suramin therapy.
Cancer 1996;78(11):2411-20.
1996: Mani S; Ratain M J
Promising new agents in oncologic treatment.
Current opinion in oncology 1996;8(6):525-34.
1996: Kobayashi K; Vokes E E; Vogelzang N J; Janisch L; Soliven B; Ratain M J
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2622-3.
1996: Mick R; Gupta E; Vokes E E; Ratain M J
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):2012-9.
1996: Fleming G F; Janisch L; Vogelzang N J; Vokes E E; Ratain M J
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
Cancer 1996;77(11):2308-12.
1996: Vokes E E; Mick R; Kies M S; Dolan M E; Malone D; Athanasiadis I; Haraf D J; Kozloff M; Weichselbaum R R; Ratain M J
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1663-71.
1996: Mick R; Vokes E E; Lestingi T M; Gray-Stern W; Fleming G F; Schilsky R L; Ratain M J
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
Clinical pharmacology and therapeutics 1996;59(3):349-59.
1996: Gupta E; Safa A R; Wang X; Ratain M J
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
Cancer research 1996;56(6):1309-14.
1996: Ratain M J; Mick R; Janisch L; Berezin F; Schilsky R L; Vogelzang N J; Kut M
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Pharmacogenetics 1996;6(1):93-101.
1996: Minami H; Beijnen J H; Verweij J; Ratain M J
Limited sampling model for area under the concentration time curve of total topotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):43-6.
1996: Larson R A; Mick R; Spielberger R T; O'Brien S M; Ratain M J
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):188-95.
1996: Minami H; Ratain M J; Ando Y; Shimokata K
Pharmacodynamic modeling of prolonged administration of etoposide.
Cancer chemotherapy and pharmacology 1996;39(1-2):61-6.
1995: Gupta E; Olopade O I; Ratain M J; Mick R; Baker T M; Berezin F K; Benson A B; Dolan M E
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(10):1133-8.
1995: Kobayashi K; Vokes E E; Vogelzang N J; Janish L; Soliven B; Ratain M J
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2196-207.
1995: Daugherty C; Ratain M J; Grochowski E; Stocking C; Kodish E; Mick R; Siegler M
Perceptions of cancer patients and their physicians involved in phase I trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1062-72.
1995: Ratain M J; Rosner G; Allen S L; Costanza M; Van Echo D A; Henderson I C; Schilsky R L
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):741-7.
1995: Larson R A; Geller R B; Janisch L; Milton J; Grochow L B; Ratain M J
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Cancer chemotherapy and pharmacology 1995;36(3):204-10.
1994: Mick R; Lane N; Daugherty C; Ratain M J
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.
Journal of the National Cancer Institute 1994;86(22):1685-93.
1994: Janisch L; Mick R; Schilsky R L; Vogelzang N J; O'Brien S; Kut M; Ratain M J
Prognostic factors for survival in patients treated in phase I clinical trials.
Cancer 1994;74(7):1965-73.
1994: Mick R; Ratain M J
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.
Clinical pharmacology and therapeutics 1994;56(2):217-22.
1994: Gupta E; Lestingi T M; Mick R; Ramirez J; Vokes E E; Ratain M J
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Cancer research 1994;54(14):3723-5.
1994: Platanias L C; Ratain M J; O'Brien S; Larson R A; Vardiman J W; Shaw J P; Williams S F; Baron J M; Parker K; Woodworth T G
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Leukemia & lymphoma 1994;14(3-4):257-62.
1994: Kobayashi K; Vogelzang N J; O'Brien S M; Schilsky R L; Vokes E E; Ratain M J
A phase I study of intermittent infusion cladribine in patients with solid tumors.
Cancer 1994;74(1):168-73.
1994: Fleming G F; Ratain M J; O'Brien S M; Schilsky R L; Hoffman P C; Richards J M; Vogelzang N J; Kasunic D A; Earhart R H
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
Journal of the National Cancer Institute 1994;86(5):368-72.
1994: Vogelzang N J; Mick R; Janisch L; Berezin F; Schilsky R L; Ratain M J
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Cancer research 1994;54(1):114-9.
1994: Kobayashi K; Ratain M J
Pharmacodynamics and long-term toxicity of etoposide.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S64-8.
1994: Mitchell R B; Dolan M E; Janisch L; Vogelzang N J; Ratain M J; Schilsky R L
Sequential therapy with dacarbazine and carmustine: a phase I study.
Cancer chemotherapy and pharmacology 1994;34(6):509-14.
1994: Spielberger R T; Mick R; Ratain M J; Golomb H M
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.
Leukemia & lymphoma 1994;14 Suppl 1():89-93.
1993: Ratain M J; Mick R; Schilsky R L; Siegler M
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
Journal of the National Cancer Institute 1993;85(20):1637-43.
1993: Samuels B L; Mick R; Vogelzang N J; Williams S F; Schilsky R L; Safa A R; O'Brien S M; Ratain M J
Modulation of vinblastine resistance with cyclosporine: a phase I study.
Clinical pharmacology and therapeutics 1993;54(4):421-9.
1993: Vokes E E; Dolan M E; Krishnasamy S; Mick R; Ratain M J; Berezin F; Brachman D; Whitman G; Schilsky R L; Charette J
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(7):591-5.
1993: Ratain M J; Mick R; Berezin F; Janisch L; Schilsky R L; Vogelzang N J; Lane L B
Phase I study of amonafide dosing based on acetylator phenotype.
Cancer research 1993;53(10 Suppl):2304-8.
1993: Ratain M J; Priest E R; Janisch L; Vogelzang N J
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a.
Cancer 1993;71(7):2371-6.
1993: Schilsky R L; Janisch L; Berezin F; Mick R; Vogelzang N J; Ratain M J
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
Cancer research 1993;53(6):1293-6.
1993: Kobayashi K; Ratain M J
Individualizing dosing of cancer chemotherapy.
Seminars in oncology 1993;20(1):30-42.
1993: Vokes E E; Ratain M J; Mick R; McEvilly J M; Haraf D; Kozloff M; Hamasaki V; Weichselbaum R R; Panje W R; Wenig B
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(2):360-8.
1993: Mick R; Ratain M J
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
Journal of the National Cancer Institute 1993;85(3):217-23.
1993: Schilsky R L; Ratain M J; Janisch L; Vogelzang N J; Lucas V S; Ravitch J; Hohneker J A; Clendeninn N J; Tuttle R L
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
Cancer chemotherapy and pharmacology 1993;31(4):283-8.
1993: Vokes E E; O'Brien S M; Vogelzang N J; Schilsky R L; Ratain M J
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
Cancer chemotherapy and pharmacology 1993;32(5):347-52.
1993: Mick R; Ratain M J
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions.
Cancer chemotherapy and pharmacology 1993;33(1):1-9.
1992: Kobayashi K; Ratain M J
New perspectives on the toxicity of etoposide.
Seminars in oncology 1992;19(6 Suppl 13):78-83.
1992: Kobayashi K; Vokes E E; Stefansson K; Janisch L; Vogelzang N J; Berezin F; Ratain M J
Suramin: is adaptive control necessary?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(12):1984-5; author reply 1985-6.
1992: Golomb H M; Ratain M J; Mick R; Daly K
Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(11):1177-80.
1992: Kodish E; Stocking C; Ratain M J; Kohrman A; Siegler M
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1810-6.
1992: Ratain M J
Therapeutic relevance of pharmacokinetics and pharmacodynamics.
Seminars in oncology 1992;19(4 Suppl 11):8-13.
1992: Schilsky R L; Ratain M J; Vokes E E; Vogelzang N J; Anderson J; Peterson B A
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
Seminars in oncology 1992;19(3 Suppl 9):84-9.
1992: Ratain M J; Rowley J D
Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(2):107-11.
1992: Miller C B; Platanias L C; Mills S R; Zahurak M L; Ratain M J; Ettinger D S; Jones R J
Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia.
Journal of the National Cancer Institute 1992;84(2):98-103.
1992: Vokes E E; Moormeier J A; Ratain M J; Egorin M J; Haraf D J; Mick R; Weichselbaum R R
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Cancer chemotherapy and pharmacology 1992;29(3):178-84.
1992: Golomb H M; Ratain M J; Mick R; Daly K
The treatment of hairy cell leukemia: an update.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():24-7.
1991: Mick R; Ratain M J
Modeling interpatient pharmacodynamic variability of etoposide.
Journal of the National Cancer Institute 1991;83(21):1560-4.
1991: Platanias L C; Miller C B; Mick R; Hart R D; Ozer H; McEvilly J M; Jones R J; Ratain M J
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(11):2021-6.
1991: Ratain M J; Mick R; Berezin F; Janisch L; Schilsky R L; Williams S F; Smiddy J
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Clinical pharmacology and therapeutics 1991;50(5 Pt 1):573-9.
1991: Ratain M J; Mick R; Schilsky R L; Vogelzang N J; Berezin F
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(8):1480-6.
1991: Ratain M J; Robert J; van der Vijgh W J
Limited sampling models for doxorubicin pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(5):871-6.
1991: Vokes E E; Raschko J W; Vogelzang N J; Warfield E E; Ratain M J; Doroshow J H; Schilsky R L
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
Cancer chemotherapy and pharmacology 1991;28(1):69-73.
1991: Platanias L C; Ratain M J
Hairy cell leukaemia: the role of alpha interferon.
European journal of cancer (Oxford, England : 1990) 1991;27 Suppl 4():S53-7.
1990: Richards J M; Mick R; Latta J M; Daly K; Ratain M J; Vardiman J W; Golomb H M
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
Blood 1990;76(10):1941-5.
1990: Ratain M J; Schilsky R L; Conley B A; Egorin M J
Pharmacodynamics in cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1739-53.
1990: Schilsky R L; Ratain M J
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration.
Journal of the National Cancer Institute 1990;82(17):1411-5.
1990: Doane L L; Ratain M J; Golomb H M
Hairy cell leukemia. Current management.
Hematology/oncology clinics of North America 1990;4(2):489-502.
1989: Johnston C; Senekjian E K; Ratain M J; Talerman A
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report.
Gynecologic oncology 1989;35(3):391-4.
1989: Moormeier J A; Ratain M J; Westbrook C A; Vardiman J W; Daly K M; Golomb H M
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
Journal of the National Cancer Institute 1989;81(15):1172-4.
1989: Ackland S P; Ratain M J; Vogelzang N J; Choi K E; Ruane M; Sinkule J A
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin.
Clinical pharmacology and therapeutics 1989;45(4):340-7.
1989: Ratain M J; Schilsky R L; Choi K E; Guarnieri C; Grimmer D; Vogelzang N J; Senekjian E; Liebner M A
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
Clinical pharmacology and therapeutics 1989;45(3):226-33.
1989: Choi K E; Ratain M J; Williams S F; Golick J A; Beschorner J C; Fullem L J; Bitran J D
Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
Cancer research 1989;49(5):1318-21.
1989: Vokes E E; Schilsky R L; Choi K E; Magid D M; Guarnieri C M; Whaling S M; Ratain M J; Weichselbaum R R; Panje W R
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
Cancer 1989;63(1):30-6.
1988: Ratain M J; Vardiman J W; Barker C M; Golomb H M
Prognostic variables in hairy cell leukemia after splenectomy as initial therapy.
Cancer 1988;62(11):2420-4.
1988: Ratain M J; Schilsky R L; Wojack B R; Simon T; Senekjian E K; Vogelzang N J
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
Journal of the National Cancer Institute 1988;80(17):1412-6.
1988: Ratain M J; Golomb H M; Vardiman J W; Westbrook C A; Barker C; Hooberman A; Bitter M A; Daly K
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(11):1714-21.
1988: Golomb H M; Fefer A; Golde D W; Ozer H; Portlock C; Silber R; Rappeport J; Ratain M J; Thompson J; Bonnem E
Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.
Seminars in oncology 1988;15(5 Suppl 5):7-9.
1988: Vardiman J W; Gilewski T A; Ratain M J; Bitter M A; Bradlow B A; Golomb H M
Evaluation of Leu-M5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique.
American journal of clinical pathology 1988;90(3):250-6.
1988: Lembersky B C; Ratain M J; Golomb H M
Skeletal complications in hairy cell leukemia: diagnosis and therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(8):1280-4.
1988: Ratain M J; Staubus A E; Schilsky R L; Malspeis L
Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
Cancer research 1988;48(14):4127-30.
1988: Ackland S P; Choi K E; Ratain M J; Egorin M J; Williams S F; Sinkule J A; Bitran J D
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(7):1192-6.
1988: Golomb H M; Ratain M J; Fefer A; Thompson J; Golde D W; Ozer H; Portlock C; Silber R; Rappeport J; Bonnem E
Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia.
Journal of the National Cancer Institute 1988;80(5):369-73.
1988: Lembersky B C; Ratain M J; Westbrook C; Golomb H M
Rapid response to 2'-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma.
American journal of hematology 1988;27(1):60-2.
1987: Vogelzang N J; Ruane M; Ratain M J; Dhowlatshahi K; Chodak G W
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(12):1968-76.
1987: Ratain M J; Kaminer L S; Bitran J D; Larson R A; Le Beau M M; Skosey C; Purl S; Hoffman P C; Wade J; Vardiman J W
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.
Blood 1987;70(5):1412-7.
1987: Ratain M J; Vogelzang N J
Limited sampling model for vinblastine pharmacokinetics.
Cancer treatment reports 1987;71(10):935-9.
1987: Golomb H M; Fefer A; Golde D W; Ozer H; Portlock C; Silber R; Rappeport J; Ratain M J; Thompson J; Bonnem E M
Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.
Seminars in oncology 1987;14(2 Suppl 2):13-7.
1987: Vokes E E; Bitter M A; Ratain M J; Prystowsky M B; Daly K; Golomb H M
Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy.
Cancer 1987;59(12):1987-91.
1987: Bardawil R G; Ratain M J; Golomb H M; Bitter M A; Groves C; Vardiman J W
Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1987;1(4):340-3.
1987: Ratain M J; Golomb H M; Bardawil R G; Vardiman J W; Westbrook C A; Kaminer L S; Lembersky B C; Bitter M A; Daly K
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia.
Blood 1987;69(3):872-7.
1986: Bardawil R G; Groves C; Ratain M J; Golomb H M; Vardiman J W
Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell leukemia.
American journal of clinical pathology 1986;85(2):194-201.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Mark Ratain

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Occupations

Activities & Behaviors

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Mark Ratain (preview)

All Publications